Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2017 Filed Feb 9, 2017 19:29 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004725 · form4.xml · derivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:26 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004722 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:28 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004724 · form4.xml · derivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:24 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004720 · form4.xml · derivative · entry 1 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:25 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004721 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:23 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004719 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:22 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004718 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 20:21 UTC |
KING DAVID PDirector · President & CEO
|
GiftCommon Stock | 31,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-067396 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 31,601 F2 · ownership.nature: On November 14, 2016, the reporting person contributed 31,601 shares of common stock to a grantor retained annuity trust for the benefit of certain of his family members and for which the reporting person is the annuitant. The reporting person is the trustee of the trust. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 20:21 UTC |
KING DAVID PDirector · President & CEO
|
GiftCommon Stock | 31,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-067396 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,104.0553 F1 · balance_after: Amount includes 160.8041 shares acquired on June 30, 2016 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan and annuity payments from each of the reporting person's grantor retained annuity trusts to the reporting person in the amounts and on the dates indicated in notes 3 and 4 below. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:57 UTC |
Ratliff John DCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 18,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064300 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 18,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.